Document is current
Any future updates will be listed below
-
Authors
Butler, Daniel https://orcid.org/0000-0002-6717-545X
Ambite, Ines
Wan, Murphy Lam Yim https://orcid.org/0000-0003-1470-671X
Tran, Thi Hien
Wullt, Björn
Svanborg, Catharina https://orcid.org/0000-0001-8145-0553
- License Information
-
More Information
Article History
Accepted: 22 April 2022
First Online: 22 June 2022
Competing interests
: Patents have been filed with the scientists as inventors for the therapeutic use of the NlpD protein, IRF7 siRNA, IL-1R antagonists, MMP and NK1R inhibitors for treating urinary tract infections. The rights to develop these patents are held by SelectImmune Pharma, where the scientists hold shares. Patents for the MYC inhibitor have also been filed for treating cancer and infections.
